Baidu
map

Sci Rep:病理性近视眼中的Cilioretinal动脉和Cilioretinal静脉情况调查

2019-04-09 不详 网络

日本东京东京医科齿科大学眼科学与视觉科学系的Watanabe T等人近日在Sci Rep杂志上发表了一篇研究论文,他们研究了病理性近视眼中的纤毛视网膜动脉(CAs)和脊髓静脉曲张(CV)的临床特征。

日本东京东京医科齿科大学眼科学与视觉科学系的Watanabe T等人近日在Sci Rep杂志上发表了一篇研究论文,他们研究了病理性近视眼中的纤毛视网膜动脉(CAs)和脊髓静脉曲张(CV)的临床特征。

他们总共研究了95只患有病理性近视和CA的眼睛。通过吲哚青绿血管造影术(ICGA)鉴定CA的眼球后血管。结果显示,在95只眼中共发现了114个CA。ICGA显示60%的CA是直接来自睫状体后部动脉(SPCA)的分支,40%来自Zinn-Haller动脉环(ZHAC)。 SPCA衍生的CA更倾向在大的视网膜区域中,而ZHAC相关的CA倾向在黄斑区域。在95只眼中,约有15%观察到CV平行于CA。CV在CA进入眼睛的同一点。

综上,这项研究表明,病理性近视眼中的CA可以分为SPCA衍生的和ZHAC衍生的。SPCA衍生的CA往往出现在视盘区的上部,ZHAC衍生的CA倾向在黄斑区域位置。

原文出处:

Watanabe, T., et al., Cilioretinal Arteries and Cilioretinal Veins in Eyes with Pathologic Myopia. Sci Rep, 2019. 9(1): p. 2451

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1793322, encodeId=eb281e93322ec, content=<a href='/topic/show?id=ebd1153e774' target=_blank style='color:#2F92EE;'>#Retinal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15377, encryptionId=ebd1153e774, topicName=Retinal)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Mon Mar 02 20:36:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783212, encodeId=95081e83212ed, content=<a href='/topic/show?id=1ef54e12c0' target=_blank style='color:#2F92EE;'>#Cilioretinal静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4712, encryptionId=1ef54e12c0, topicName=Cilioretinal静脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Aug 06 05:36:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793313, encodeId=82ec1e93313fe, content=<a href='/topic/show?id=5400153e639' target=_blank style='color:#2F92EE;'>#Retina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15376, encryptionId=5400153e639, topicName=Retina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Jun 27 14:36:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913903, encodeId=4aa11913903b1, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun May 19 08:36:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697885, encodeId=f801169e8858a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Dec 07 14:36:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364381, encodeId=8dc036438112, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Apr 09 21:57:38 CST 2019, time=2019-04-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1793322, encodeId=eb281e93322ec, content=<a href='/topic/show?id=ebd1153e774' target=_blank style='color:#2F92EE;'>#Retinal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15377, encryptionId=ebd1153e774, topicName=Retinal)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Mon Mar 02 20:36:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783212, encodeId=95081e83212ed, content=<a href='/topic/show?id=1ef54e12c0' target=_blank style='color:#2F92EE;'>#Cilioretinal静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4712, encryptionId=1ef54e12c0, topicName=Cilioretinal静脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Aug 06 05:36:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793313, encodeId=82ec1e93313fe, content=<a href='/topic/show?id=5400153e639' target=_blank style='color:#2F92EE;'>#Retina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15376, encryptionId=5400153e639, topicName=Retina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Jun 27 14:36:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913903, encodeId=4aa11913903b1, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun May 19 08:36:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697885, encodeId=f801169e8858a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Dec 07 14:36:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364381, encodeId=8dc036438112, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Apr 09 21:57:38 CST 2019, time=2019-04-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1793322, encodeId=eb281e93322ec, content=<a href='/topic/show?id=ebd1153e774' target=_blank style='color:#2F92EE;'>#Retinal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15377, encryptionId=ebd1153e774, topicName=Retinal)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Mon Mar 02 20:36:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783212, encodeId=95081e83212ed, content=<a href='/topic/show?id=1ef54e12c0' target=_blank style='color:#2F92EE;'>#Cilioretinal静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4712, encryptionId=1ef54e12c0, topicName=Cilioretinal静脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Aug 06 05:36:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793313, encodeId=82ec1e93313fe, content=<a href='/topic/show?id=5400153e639' target=_blank style='color:#2F92EE;'>#Retina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15376, encryptionId=5400153e639, topicName=Retina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Jun 27 14:36:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913903, encodeId=4aa11913903b1, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun May 19 08:36:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697885, encodeId=f801169e8858a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Dec 07 14:36:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364381, encodeId=8dc036438112, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Apr 09 21:57:38 CST 2019, time=2019-04-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1793322, encodeId=eb281e93322ec, content=<a href='/topic/show?id=ebd1153e774' target=_blank style='color:#2F92EE;'>#Retinal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15377, encryptionId=ebd1153e774, topicName=Retinal)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Mon Mar 02 20:36:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783212, encodeId=95081e83212ed, content=<a href='/topic/show?id=1ef54e12c0' target=_blank style='color:#2F92EE;'>#Cilioretinal静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4712, encryptionId=1ef54e12c0, topicName=Cilioretinal静脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Aug 06 05:36:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793313, encodeId=82ec1e93313fe, content=<a href='/topic/show?id=5400153e639' target=_blank style='color:#2F92EE;'>#Retina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15376, encryptionId=5400153e639, topicName=Retina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Jun 27 14:36:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913903, encodeId=4aa11913903b1, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun May 19 08:36:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697885, encodeId=f801169e8858a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Dec 07 14:36:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364381, encodeId=8dc036438112, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Apr 09 21:57:38 CST 2019, time=2019-04-09, status=1, ipAttribution=)]
    2019-05-19 ysjykql
  5. [GetPortalCommentsPageByObjectIdResponse(id=1793322, encodeId=eb281e93322ec, content=<a href='/topic/show?id=ebd1153e774' target=_blank style='color:#2F92EE;'>#Retinal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15377, encryptionId=ebd1153e774, topicName=Retinal)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Mon Mar 02 20:36:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783212, encodeId=95081e83212ed, content=<a href='/topic/show?id=1ef54e12c0' target=_blank style='color:#2F92EE;'>#Cilioretinal静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4712, encryptionId=1ef54e12c0, topicName=Cilioretinal静脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Aug 06 05:36:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793313, encodeId=82ec1e93313fe, content=<a href='/topic/show?id=5400153e639' target=_blank style='color:#2F92EE;'>#Retina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15376, encryptionId=5400153e639, topicName=Retina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Jun 27 14:36:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913903, encodeId=4aa11913903b1, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun May 19 08:36:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697885, encodeId=f801169e8858a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Dec 07 14:36:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364381, encodeId=8dc036438112, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Apr 09 21:57:38 CST 2019, time=2019-04-09, status=1, ipAttribution=)]
    2019-12-07 fusion
  6. [GetPortalCommentsPageByObjectIdResponse(id=1793322, encodeId=eb281e93322ec, content=<a href='/topic/show?id=ebd1153e774' target=_blank style='color:#2F92EE;'>#Retinal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15377, encryptionId=ebd1153e774, topicName=Retinal)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Mon Mar 02 20:36:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783212, encodeId=95081e83212ed, content=<a href='/topic/show?id=1ef54e12c0' target=_blank style='color:#2F92EE;'>#Cilioretinal静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4712, encryptionId=1ef54e12c0, topicName=Cilioretinal静脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Aug 06 05:36:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793313, encodeId=82ec1e93313fe, content=<a href='/topic/show?id=5400153e639' target=_blank style='color:#2F92EE;'>#Retina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15376, encryptionId=5400153e639, topicName=Retina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Jun 27 14:36:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913903, encodeId=4aa11913903b1, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun May 19 08:36:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697885, encodeId=f801169e8858a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Dec 07 14:36:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364381, encodeId=8dc036438112, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Apr 09 21:57:38 CST 2019, time=2019-04-09, status=1, ipAttribution=)]
    2019-04-09 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

儿童青少年近视眼检测与防控的应用标准

根据中国医学装备协会眼科专业委员会,于2016年4 月15 日发布的OCC-HYBZ[2016〗第001 号“关于启动眼科医药装备行业标准评定的通知”精神,中国医学装备协会眼科专业委员会组织相关专家对儿童青少年近视眼检测与防控的应用标准( 2018) Application standard for detection and prevention of myopia in children an

到2017年,世上可能就没有近视眼了

近视眼的痛,你懂吗? 近视眼的世界是这样的: 现在,新科技来拯救近视眼了! 据报道,加拿大一家科技公司Ocumetics的执行长加思·韦伯(GARTH WEBB)斥资300多万美金,与研究团队耗费8年时间,终于开发出一种高科技仿生镜片。 研究人员表示:戴上这种仿生镜片后,只要短短10秒钟,就可以让视力快速恢复!而原先不良的视力不但能够被矫正,还能比1.0的视力好出两

为什么中国的近视率如此之高?

现如今,亚洲人的眼睛健康状况着实令人担忧。这听起来非常离谱,但事实上几乎90%的中国青少年都是近视眼。   遗传  长期以来,科学界的共识一直认为近视是由遗传导致的。上世纪60年代的研究表明,基因和眼睛状况之间有明确的联系,表现出很强的DNA易受性。但很快就有证据表明基因并不能负全部责任。1969年的一项因纽特人研究明确地表明了这点。在一个孤立的社群中,131个人中只有2个是近

近视眼要不要一直戴眼镜,配镜有何讲究

人的一生中,或早或晚都要与眼镜打交道。有近视的要佩戴矫正近视的眼镜,有远视的要佩戴矫正远视的眼镜,有散光的要佩戴矫正散光的眼镜。就算你是正视眼,到了中老年,老视眼(即老花眼)就会找上门来,还非得配副老花眼镜。那么,近视眼应该配框架眼镜还是隐形眼镜?配镜之后,需要一直佩戴吗?这些问题都是近视患者的共同困惑,就让我们聊聊关于眼镜的那些事。配眼镜有何讲究不论是近视、远视、散光,在医学上都称为屈光不正。老

近视眼的福利 国家眼科工程中心研制出高精度镜片

随着国家经济实力的增强,科学技术的飞速发展,我国屈光不正的人数在飞速上升。但与此相对应的是,大量近视眼的国人却没有佩戴最适合自己的眼镜。4月7日,在“2018精密数字制造与未来视光学国际论坛”上,首都医科大学附属北京同仁医院眼科中心主任、国家眼科诊断与治疗工程技术研究中心主任王宁利宣布,相关机构已经设计制造出以5度进阶的高精度光学镜片。一场由人工智能和眼科专家进行的人机大战在当天的论坛中上演,尽

PLoS Medicine:刘奕志团队创建近视眼人工智能预测模型

11月8日,记者从中山大学中山眼科中心获悉,该中心教授刘奕志团队利用百万医学验光大数据,创建了近视眼人工智能预测模型,可对近视进展趋势进行个体化预测。相关研究11月6日在线发表在《公共科学图书馆—医学》(PLoS Medicine)官网首页。

Baidu
map
Baidu
map
Baidu
map